Keith R. Leonard - 02 Mar 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Keith Leonard
Issuer symbol
ARQT
Transactions as of
02 Mar 2026
Net transactions value
-$997,195
Form type
4
Filing time
04 Mar 2026, 16:17:39 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Leonard Keith R Director C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Keith Leonard 04 Mar 2026 0001416180

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise +27,052 +122% $8.63* 49,175 02 Mar 2026 Direct F1
transaction ARQT Common Stock Options Exercise +12,220 +25% $7.51* 61,395 02 Mar 2026 Direct F1
transaction ARQT Common Stock Sale $997,195 -39,272 -64% $25.39 22,123 02 Mar 2026 Direct F1, F2
holding ARQT Common Stock 1,750 02 Mar 2026 By Leonard Family Trust dated August 28, 1996 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise -27,052 -100% $0.000000* 0 02 Mar 2026 Common Stock 27,052 $8.63 Direct F1, F4
transaction ARQT Stock Option (right to buy) Options Exercise -12,220 -100% $0.000000* 0 02 Mar 2026 Common Stock 12,220 $7.51 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on November 18, 2025, by the Reporting Person, with a plan end date of February 16, 2027.
F2 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.05 to $26.039, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Shares held by Leonard Family Trust dated August 28, 1996, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F4 The option is fully vested.